KAZIA THERAPEUTICS LTD

Kazia Therapeutics Limited is a clinical-stage biotechnology company that focuses on the development of anti-cancer drug candidates. The company directs its operations toward targeted cancer therapies, concentrating on core pipeline assets including paxalisib, an investigational treatment for brain cancers and solid tumors, and EVT801, a selective VEGFR-3 inhibitor, alongside research associated with cantrixil. Kazia commercializes and advances its pipeline by partnering with international pharmaceutical and biotechnology enterprises through commercial and territory-based licensing agreements.

The organization conducts activities through operating entities such as Kazia Laboratories Pty Ltd, Kazia Research Pty Ltd, Kazia Therapeutics Inc., and Glioblast Pty Ltd. Kazia Therapeutics maintains operations across Australia and the United States, and holds licensing agreements spanning multiple jurisdictions, including collaborations connected to entities in China, South Korea, Sweden, and Israel. The company's corporate structure is anchored in Australia, with operational and regulatory activities extending across both Australia and the United States.

Summary of the business section of Kazia Therapeutics's latest annual report, written by StockData.

“The consolidated entity employed 14 people at June 30, 2015, 12 people at June 30, 2014, and 5 people at June 30, 2013 as follows:”